INNOVATIVE EYEWEAR INC (LUCY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$0.93+2.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · LUCY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue efforts to increase sales aiming for $2.7 million revenue in fiscal year 2025, representing a substantial year-over-year increase.
Stated as a priority in 3 recent quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Guidance projects 2025 full-year revenue at $2.7 million, a 65% increase from $1.6 million in 2024. Quarterly revenue grew from $773,561 in 2026-Q1 to $1,010,519 in 2026-Q2, showing progress toward the growth target and delivering on stated priorities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Over the trailing year it converted 0.90x of net income into operating cash flow.
Not enough signal yet.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Management continues to focus on driving revenue growth toward $2.7 million in 2025.”
“We remain committed to achieving the $2.7 million revenue target for 2025.”
“Preliminary full-year 2025 sales are estimated at $2.7 million, up 65% from 2024.”
Focus on increasing gross profit margins and reducing net losses to improve overall financial health.
Stated as a priority in 5 quarters from 2025-Q2 through 2026-Q2. Gross profit improved significantly from a negative $12,665 in 2025-Q2 to $242,515 in 2026-Q2. Net losses decreased from -$2.1 million to -$1.67 million over the same period. The trajectory shows delivering progress on improving profitability and reducing losses.
“We continue to focus on improving gross profit and reducing net losses.”
“Improving gross profit and reducing net losses remains a key priority.”
“Efforts to improve gross profit and reduce net losses are ongoing.”
“Focus on gross profit improvement and net loss reduction continues.”
“Improving gross profit and reducing net losses is a priority.”
Execute capital allocation strategies including warrant exercises and issuance to support working capital and corporate purposes.
Newly stated in 2026-Q3 via 8-K exhibit on July 9, 2026. The company announced warrant exercises expected to generate approximately $3.0 million in gross proceeds and issuance of new Series J warrants with potential proceeds of $7.25 million. This reflects active capital allocation management through warrant transactions.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.